{"id":591,"date":"2013-08-01T12:04:00","date_gmt":"2013-08-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/sprue-aehnliche-enteropathie-unter-olmesartan"},"modified":"2013-08-01T12:04:00","modified_gmt":"2013-08-01T10:04:00","slug":"sprue-aehnliche-enteropathie-unter-olmesartan","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/sprue-aehnliche-enteropathie-unter-olmesartan","title":{"rendered":"Sprue-\u00e4hnliche Enteropathie unter Olmesartan"},"content":{"rendered":"<p>Die FDA hat in einer \u201eSafety Communication\u201d vor einer schweren gastrointestinalen UAW des Angiotensin-II-Rezeptor-Blockers (AT-II-RB) Olmesartan (Olmetec\u00ae, Votum\u00ae, Mencord\u00ae; mehrere Kombinationspr\u00e4parate mit Thiaziddiuretika und Amlodipin) gewarnt und eine entsprechende \u00c4nderung der Gebrauchsinformation verf\u00fcgt (1). Bei der UAW handelt es sich um eine Sprue-\u00e4hnliche Enteropathie, charakterisiert durch chronische Diarrh\u00f6 mit ausgepr\u00e4gtem Gewichtsverlust. Die Symptome, k\u00f6nnen bis [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die FDA hat in einer \u201eSafety Communication\u201d vor einer schweren gastrointestinalen UAW des Angiotensin-II-Rezeptor-Blockers (AT-II-RB) Olmesartan (Olmetec\u00ae, Votum\u00ae, Mencord\u00ae; mehrere Kombinationspr\u00e4parate mit Thiaziddiuretika und Amlodipin) gewarnt und eine entsprechende \u00c4nderung der Gebrauchsinformation verf\u00fcgt (1). Bei der UAW handelt es sich um eine Sprue-\u00e4hnliche Enteropathie, charakterisiert durch chronische Diarrh\u00f6 mit ausgepr\u00e4gtem Gewichtsverlust. Die Symptome, k\u00f6nnen bis [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[316,309,312,314,313,315,317,320,311,307,319,310,1311,306],"class_list":["post-591","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-olmesartan","tag-sartane"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=591"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/591\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}